Trial Profile
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Burosumab (Primary) ; Burosumab (Primary) ; Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Therapeutic Use
- Sponsors Kyowa Kirin Pharmaceutical Development
- 19 May 2022 Status changed from active, no longer recruiting to completed.
- 03 Dec 2021 Results of post-hoc analysis (n=131) assessing utility change over time was estimated using asymptotic models fitted to the placebo data to week 24 from UX023-CL303, and the burosumab data to week 48 from BUR02 studies, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 31 Aug 2021 Status changed from recruiting to active, no longer recruiting.